Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Impact of nonsynonymous single nucleotide polymorphisms on in-vitro metabolism of exemestane by hepatic cytosolic reductases.

Pharmacogenetics and genomics - 1 Aug 2016

Platt Amity, Xia Zuping, Liu Ying, Chen Gang, Lazarus Philip

Abstract excerpt

OBJECTIVE: Exemestane (EXE) is a potent third-generation aromatase inhibitor used as endocrine therapy in breast cancer treatment and prevention. Characterization of its metabolic pathway is incomplete, with ambiguity existing in the identity of enzymes driving the production of its key metabolite, 17β-dihydroexemestane (17β-DHE). The impact of genetic variation on EXE metabolism is also unknown. This study aims...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Androstadienes
Share to Catalysis
Share to Cytosol

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to In Vitro Techniques

Share to Metabolomics

Share to Oxidoreductases

Share to Tandem Mass Spectrometry

Source

Open in PubMed Open full text

Identifiers

PMID: 27111237
DOI: 10.1097/FPC.0000000000000226
PMCID: PMC5088049

Genes

CBR1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Impact of nonsynonymous single nucleotide polymorphisms on in-vitro metabolism of exemestane by hepatic cytosolic reductases.PMID 27111237Read ↗

Pharmacogenetics of aldo-keto reductase 1C (AKR1C) enzymes.Semantic proximity Read ↗

Influence of glutathione-S-transferase polymorphisms on the metabolism of the potent aromatase inhibitor, exemestaneSemantic proximity Read ↗

Structural and Functional Biology of Aldo-Keto Reductase Steroid-Transforming EnzymesSemantic proximity Read ↗

Pharmacogenomics of third-generation aromatase inhibitors.Semantic proximity Read ↗

Polymorphisms in drug-metabolizing enzymes and steady-state exemestane concentration in postmenopausal patients with breast cancer.Semantic proximity Read ↗

Role of aldo-keto reductase family 1 (AKR1) enzymes in human steroid metabolism.Semantic proximity Read ↗

SLCO1B1 polymorphisms and plasma estrone conjugates in postmenopausal women with ER+ breast cancer: genome-wide association studies of the estrone pathway.Semantic proximity Read ↗

Molecular insights into CYP19A1 mutations and their role in estrogen production.Semantic proximity Read ↗

Clinical implications of genetic variation in carboxylesterase drug metabolism.Semantic proximity Read ↗

Differential activity and expression of human 5β-reductase (AKR1D1) splice variantsSemantic proximity Read ↗

In Vitro Evaluation of the Reductase Activities of Human AKR1C3 Allelic Variants.Semantic proximity Read ↗

Influence of Glutathione-S-Transferase A1*B Allele on the Metabolism of the Aromatase Inhibitor, Exemestane, in Human Liver Cytosols and in Patients Treated With Exemestane.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.